Indicated for cervical cancer screening for women between the ages of 24 and 65.
The source, specimen adequacy, descriptions, and additional findings are noted, along with recommended follow-up steps.
Aptima® HPV Assay
Positive results indicate qualitative detection of E6/E7 viral messenger RNA (mRNA) of any one or more of the high-risk types of HPV in the cervical specimen. Negative results indicate HPV E6/E7 mRNA was not detected.
High-risk HPV types detected include 16, 18, 31, 33, 35, 39, 45, 58, 59, and 68.
Aptima Combo 2® Assay
Positive results diagnose chlamydia and/or gonococcal urogenital disease.